DE69713336T2 - Verfahren zur Herstellung von aktivierten markierten tumorspezifischen T-Zellen und deren Verwendung in der Behandlung von Tumoren - Google Patents

Verfahren zur Herstellung von aktivierten markierten tumorspezifischen T-Zellen und deren Verwendung in der Behandlung von Tumoren

Info

Publication number
DE69713336T2
DE69713336T2 DE69713336T DE69713336T DE69713336T2 DE 69713336 T2 DE69713336 T2 DE 69713336T2 DE 69713336 T DE69713336 T DE 69713336T DE 69713336 T DE69713336 T DE 69713336T DE 69713336 T2 DE69713336 T2 DE 69713336T2
Authority
DE
Germany
Prior art keywords
tumors
cells
treatment
production
specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69713336T
Other languages
English (en)
Other versions
DE69713336D1 (de
Inventor
Giulia Casorati
Paolo Dellabona
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Science Park Raf SpA
Original Assignee
Science Park Raf SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Science Park Raf SpA filed Critical Science Park Raf SpA
Application granted granted Critical
Publication of DE69713336D1 publication Critical patent/DE69713336D1/de
Publication of DE69713336T2 publication Critical patent/DE69713336T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
DE69713336T 1996-03-30 1997-03-26 Verfahren zur Herstellung von aktivierten markierten tumorspezifischen T-Zellen und deren Verwendung in der Behandlung von Tumoren Expired - Fee Related DE69713336T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96105157 1996-03-30
PCT/EP1997/001541 WO1997037004A1 (en) 1996-03-30 1997-03-26 Method for the production of activated marked tumor-specific t cells and use thereof in treatment of tumors

Publications (2)

Publication Number Publication Date
DE69713336D1 DE69713336D1 (de) 2002-07-18
DE69713336T2 true DE69713336T2 (de) 2002-12-05

Family

ID=8222631

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69713336T Expired - Fee Related DE69713336T2 (de) 1996-03-30 1997-03-26 Verfahren zur Herstellung von aktivierten markierten tumorspezifischen T-Zellen und deren Verwendung in der Behandlung von Tumoren

Country Status (8)

Country Link
US (1) US6399054B1 (de)
EP (1) EP0914416B1 (de)
JP (1) JP2000515364A (de)
AU (1) AU2160297A (de)
CA (1) CA2250394A1 (de)
DE (1) DE69713336T2 (de)
ES (1) ES2177964T3 (de)
WO (1) WO1997037004A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7541184B2 (en) * 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US20040175373A1 (en) * 2002-06-28 2004-09-09 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
US20050084967A1 (en) * 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
EP1539929B1 (de) * 2002-06-28 2013-04-10 Life Technologies Corporation Verfahren zur wiederherstellung des immunrepertoirs in patienten mit immunologischen defekten in verbindung mit autoimmunität sowie transplantation von organen oder hämatopoetischen stammzellen
CA2522700A1 (en) * 2003-04-18 2004-11-04 Cytovia, Inc. Methods of treating diseases responsive to induction of apoptosis and screening assays
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
JP5368798B2 (ja) 2005-10-31 2013-12-18 オンコメッド ファーマシューティカルズ インコーポレイテッド 癌を診断し処置するための組成物および方法
PL2032166T3 (pl) 2006-06-13 2013-09-30 Oncomed Pharm Inc Kompozycje i sposoby diagnozowania i leczenia nowotworów
JP5618544B2 (ja) 2007-01-24 2014-11-05 オンコメッドファーマシューティカルズ インコーポレイテッド 癌の診断および処置のための組成物および方法
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
EP2162469A4 (de) * 2007-05-21 2012-08-01 Alderbio Holdings Llc Neue verfahren zur humanisierung von kaninchenantikörpern und humanisierte kaninchenantikörper
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
US8404235B2 (en) 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US8252286B2 (en) 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
HUE043782T2 (hu) 2007-05-21 2019-09-30 Alderbio Holdings Llc IL-6 elleni antitestek és alkalmazásuk
US7906117B2 (en) 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
US20090238825A1 (en) * 2007-05-21 2009-09-24 Kovacevich Brian R Novel rabbit antibody humanization methods and humanized rabbit antibodies
US8178101B2 (en) * 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
CN104402998A (zh) 2008-07-08 2015-03-11 昂考梅德药品有限公司 分离的抗体
SG190568A1 (en) 2008-09-26 2013-06-28 Oncomed Pharm Inc Frizzled-binding agents and uses thereof
US8551789B2 (en) 2010-04-01 2013-10-08 OncoMed Pharmaceuticals Frizzled-binding agents and their use in screening for WNT inhibitors
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
US9452227B2 (en) * 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
WO2011066374A2 (en) 2009-11-24 2011-06-03 Alder Biopharmaceuticals, Inc. Antagonists of il-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
EP2335721A1 (de) * 2009-12-21 2011-06-22 Institut Pasteur Streptavidin und Biotin-enthaltendes Antigensversorgungssystem
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
WO2011088215A2 (en) 2010-01-13 2011-07-21 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
ES2847891T3 (es) 2010-11-23 2021-08-04 Vitaeris Inc Anticuerpos anti-IL-6 para el tratamiento de la mucositis oral
EP2911691B1 (de) 2012-10-23 2018-10-10 OncoMed Pharmaceuticals, Inc. Verfahren zur behandlung von neuroendokrinen tumoren mit wnt-pad-bindemitteln
JP2016510411A (ja) 2013-02-04 2016-04-07 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路インヒビターによる処置の方法およびモニタリング
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
DE102018108612A1 (de) 2018-03-21 2019-09-26 Immatics US, Inc. Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
WO2023137471A1 (en) 2022-01-14 2023-07-20 Tune Therapeutics, Inc. Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation
WO2023137472A2 (en) 2022-01-14 2023-07-20 Tune Therapeutics, Inc. Compositions, systems, and methods for programming t cell phenotypes through targeted gene repression
WO2024064642A2 (en) 2022-09-19 2024-03-28 Tune Therapeutics, Inc. Compositions, systems, and methods for modulating t cell function

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987004628A1 (en) * 1986-01-30 1987-08-13 Fred Hutchinson Cancer Research Center Immunoselection method
IT1245748B (it) * 1990-12-21 1994-10-14 Mini Ricerca Scient Tecnolog Preparazione includente anticorpi monoclonali biotinilati, avidina e biotina, per la diagnosi di affezioni tumorali e suo impiego
WO1995003408A1 (en) * 1993-07-26 1995-02-02 Dana-Farber Cancer Institute B7-2: ctl a4/cd 28 counter receptor

Also Published As

Publication number Publication date
EP0914416A1 (de) 1999-05-12
EP0914416B1 (de) 2002-06-12
US6399054B1 (en) 2002-06-04
JP2000515364A (ja) 2000-11-21
WO1997037004A1 (en) 1997-10-09
CA2250394A1 (en) 1997-10-09
DE69713336D1 (de) 2002-07-18
ES2177964T3 (es) 2002-12-16
AU2160297A (en) 1997-10-22

Similar Documents

Publication Publication Date Title
DE69713336T2 (de) Verfahren zur Herstellung von aktivierten markierten tumorspezifischen T-Zellen und deren Verwendung in der Behandlung von Tumoren
DE60043035D1 (de) Verfahren zur Herstellung von laminierten Ringen und Wärmebehandlungsvorrichtung zur Verwendung bei diesem Verfahren
ATE349428T1 (de) Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen
DE59804783D1 (de) Eisenoxidrotpigmente, Verfahren zur Herstellung von Eisenoxidrotpigmenten und deren Verwendung
DE59503593D1 (de) Verfahren zur Herstellung von wasserverdünnbaren Urethanharzen und deren Verwendung
DE69816758D1 (de) Synthetisches quarzglas zur verwendung in uv-strahlung und verfahren zu seiner herstellung
DE3887537D1 (de) Verbandmaterial für wundbehandlung und teilchen zur verwendung in seiner herstellung.
DE69729284D1 (de) Filmbildende zusammensetzungen von antihyperalgesischen opiaten und deren verwendung zur behandlung von hyperalgesie
DE69535674D1 (de) Verfahren zur herstellung von l-valin und l-leucin
DE69821548D1 (de) Vernetzte Polyaminsäure und deren Verfahren zur Herstellung
DE69512288D1 (de) Verfahren zur Herstellung von Hexafluorpropan und Perfluorpropan
DE59508922D1 (de) Verfahren zur Herstellung von Aminopropylalkoxysilanen in Gegenwart von geformten polymeren Rhodiumkomplex-Katalysatoren und deren Verwendung
DE69734296D1 (de) Neue dikaffeoylchinasäurederivate und deren verwendung zur behandlung von hepatitis b
DE69810735T2 (de) Zusammensetzung für die Behandlung von Wasser und deren Verfahren zur Herstellung
DE59610741D1 (de) Verfahren zur Herstellung von Deckelmaterial sowie dessen Verwendung
DE59403959D1 (de) Verfahren zur Herstellung von Diurethanen und ihrer Verwendung zur Herstellung von Diisocyanaten
DE59500700D1 (de) Verfahren und Mittel zur Herstellung von purpurfarbenen Dekoren
DE60031100D1 (de) Hapten modifizierte tumorzellen und verfahren zur herstellung und deren verwendung
DE59808352D1 (de) Verfahren zur Herstellung Superabsorber-Polymere enthaltender Körper und deren Verwendung
DE69531132D1 (de) Blattförmiger Sauerstoff-Absorber und Verfahren zur Herstellung
DE69711974T2 (de) Verfahren zur Reinigung von 2,6-Dimethylnaphthol und dessen Verwendung bei der Herstellung von 2,6-Naphtholdicarbonsäure
DE60027429D1 (de) Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien
DE59711559D1 (de) Verfahren zur Herstellung von nicht-wässrigen Dispersionen und deren Verwendung
DE69700062T2 (de) Verfahren zur Herstellung von UV-Filtern enthaltende Zusammensetzungen, Zusammensetzung und Verwendung
DE69508151T2 (de) Verfahren zur Herstellung von Verbundfolie und Verbundfolie

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee